Lactotripeptides
Introduction to Bioactive Milk Peptides
Lactotripeptides are specific sequences of three amino acids derived from the enzymatic hydrolysis or microbial fermentation of casein, the primary protein found in mammalian milk. The two most clinically significant and extensively researched lactotripeptides are Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline (IPP). Unlike intact dietary proteins that are broken down entirely into individual amino acids for muscle protein synthesis, these specific tripeptides possess unique structural characteristics—specifically the presence of proline residues—that render them highly resistant to complete degradation by gastric and pancreatic peptidases. This resistance allows them to be absorbed intact into the systemic circulation, where they exert potent physiological effects, most notably on the cardiovascular system and hemodynamics.
The Renin-Angiotensin-Aldosterone System (RAAS) and ACE Inhibition
The primary mechanism of action for VPP and IPP is the competitive inhibition of Angiotensin-Converting Enzyme (ACE), a central component of the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS is a critical regulator of blood pressure, blood volume, and systemic vascular resistance. In a typical physiological state, the liver releases angiotensinogen, which is converted by renin (released from the kidneys) into angiotensin I. Angiotensin I is a relatively inactive decapeptide. ACE, an exopeptidase primarily located on the endothelial surface of the lungs and kidneys, cleaves two amino acids from angiotensin I to form angiotensin II.
Angiotensin II is one of the most potent endogenous vasoconstrictors in the human body. It binds to AT1 receptors on vascular smooth muscle cells, triggering an intracellular cascade that leads to smooth muscle contraction and a reduction in the luminal diameter of blood vessels. By competitively binding to the active site of ACE, VPP and IPP prevent the conversion of angiotensin I to angiotensin II. The structural homology of the proline-rich sequences in VPP and IPP allows them to interact favorably with the zinc-dependent active site of ACE, effectively blocking its catalytic activity. The subsequent reduction in circulating angiotensin II levels leads to a relaxation of vascular smooth muscle, resulting in vasodilation and a decrease in peripheral vascular resistance.
The Bradykinin Preservation Pathway
The inhibition of ACE by lactotripeptides yields a secondary, yet equally vital, mechanism for enhancing vasodilation: the preservation of bradykinin. ACE is a promiscuous enzyme; in addition to synthesizing angiotensin II, it is also responsible for the degradation of bradykinin, a potent endothelium-dependent vasodilator. Bradykinin acts by binding to B2 receptors on endothelial cells, which stimulates the release of intracellular calcium. This calcium spike activates endothelial nitric oxide synthase (eNOS), the enzyme responsible for converting L-arginine into nitric oxide (NO).
By inhibiting ACE, VPP and IPP prevent the breakdown of bradykinin. The resulting accumulation of bradykinin leads to sustained eNOS activation and a continuous, robust production of nitric oxide. This NO diffuses into the adjacent vascular smooth muscle cells, activating soluble guanylyl cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP). Elevated cGMP levels cause a reduction in intracellular calcium within the smooth muscle, leading to profound relaxation and vasodilation. Therefore, lactotripeptides enhance blood flow through a dual mechanism: removing the vasoconstrictive brake (angiotensin II) and pressing the vasodilatory accelerator (bradykinin/nitric oxide).
Pharmacokinetics and Bioavailability
The pharmacokinetic profile of lactotripeptides is heavily influenced by their molecular structure. The high concentration of proline residues in VPP and IPP creates steric hindrance that protects the peptide bonds from cleavage by digestive proteases such as pepsin, trypsin, and chymotrypsin. Upon reaching the small intestine, these tripeptides are absorbed intact across the enterocyte brush border via the PEPT1 (Peptide Transporter 1) system, a proton-coupled symporter that efficiently transports di- and tripeptides.
Once in the systemic circulation, VPP and IPP exhibit a relatively rapid onset of action. Peak plasma concentrations are typically observed within 60 to 90 minutes post-ingestion, aligning perfectly with standard pre-workout supplementation timing. The half-life of these peptides in the bloodstream is relatively short, typically ranging from 2 to 4 hours, as they are eventually degraded by serum peptidases or excreted renally. However, the downstream effects of ACE inhibition and the subsequent cascade of eNOS activation and cGMP production can sustain vasodilation for several hours beyond the clearance of the peptides themselves.
Hemodynamic Responses During Exercise
In the context of sports nutrition and exercise physiology, the hemodynamic alterations induced by VPP and IPP are highly desirable. During intense resistance training, the mechanical compression of blood vessels by contracting muscles, combined with sympathetic nervous system activation, can restrict blood flow. The ACE-inhibiting properties of lactotripeptides counteract this by maintaining a vasodilatory state. This enhanced hyperemia (the 'pump') facilitates the rapid delivery of oxygen, glucose, and amino acids to the working muscles, while simultaneously accelerating the clearance of metabolic byproducts such as hydrogen ions, inorganic phosphate, and lactate. This improved microcirculation not only enhances the acute visual appearance of muscle fullness but also delays the onset of peripheral fatigue, allowing for greater training volume and improved subsequent recovery.
What is VasoDrive-AP? +
How do lactotripeptides give you a pump? +
Does VasoDrive-AP contain lactose? +
Is VasoDrive-AP safe for people with dairy allergies? +
What is the best dose of VasoDrive-AP? +
When should I take lactotripeptides? +
Can I stack VasoDrive-AP with L-Citrulline? +
Will lactotripeptides keep me awake at night? +
Do lactotripeptides lower blood pressure? +
Are lactotripeptides the same as casein protein powder? +
Can women take VasoDrive-AP? +
Do I need to cycle lactotripeptides? +
What do lactotripeptides feel like? +
Are lactotripeptides banned in sports? +
Can lactotripeptides help with muscle recovery? +
Can I take VasoDrive-AP if I am on blood pressure medication? +
Everything About Lactotripeptides Article
The Ultimate Pump Ingredient You've Never Heard Of When you think of pre-workout pump ingredients, your mind likely goes straight to L-Citrulline, Arginine, or maybe dietary nitrates like beetroot extract. These ingredients are fantastic, but they all generally work on the same side of the equation: they push the body to produce more nitric oxide. But what if you could attack muscle pumps from an entirely different angle? What if, instead of just pressing the gas pedal on nitric oxide, you could also take your foot off the brakes of vasoconstriction?
Enter Lactotripeptides, most commonly known in the sports nutrition world by the trademarked name VasoDrive-AP®. Derived from milk protein, these tiny peptide chains are revolutionizing how formulators build premium pump products. By acting as natural ACE inhibitors, lactotripeptides force your blood vessels to relax, resulting in skin-tearing pumps, enhanced endurance, and superior nutrient delivery.
What Are Lactotripeptides? Lactotripeptides are specific, bioactive sequences of three amino acids derived from casein, the slow-digesting protein found in mammalian milk. While a standard scoop of casein protein powder is broken down by your digestive system into individual amino acids to build muscle, lactotripeptides are different.
The two most important lactotripeptides are Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline (IPP). Because they contain multiple proline amino acids, their molecular structure is incredibly tough. They resist being broken down by stomach acid and digestive enzymes, allowing them to be absorbed intact into your bloodstream. Once in the blood, they don't act as building blocks for muscle; instead, they act as powerful signaling molecules that alter your cardiovascular hemodynamics.
How VasoDrive-AP Works: The Science of ACE Inhibition To understand why lactotripeptides are so effective for muscle pumps, you have to understand the Renin-Angiotensin-Aldosterone System (RAAS). This system regulates your blood pressure. A key player in this system is an enzyme called Angiotensin-Converting Enzyme (ACE).
ACE has a nasty habit (at least, when you're trying to get a pump) of converting a harmless molecule into Angiotensin II. Angiotensin II is one of the most potent vasoconstrictors in the human body—it binds to your blood vessels and forces them to squeeze shut, restricting blood flow.
Lactotripeptides (VPP and IPP) are natural ACE inhibitors. They bind to the ACE enzyme and block it from doing its job. By stopping the production of Angiotensin II, your blood vessels are allowed to relax and expand (vasodilation).
But that's only half the story. ACE is also responsible for destroying a molecule called bradykinin. Bradykinin is a powerful vasodilator that tells your blood vessels to produce nitric oxide. Because lactotripeptides inhibit ACE, bradykinin survives longer in your bloodstream. This leads to a massive, sustained release of nitric oxide. You get a dual-action pump: you stop the blood vessels from constricting, and you actively force them to open wider.
The Synergy: Why You Should Stack It With Citrulline Because lactotripeptides work via ACE inhibition, they are the ultimate stacking ingredient. If you take L-Citrulline, you are giving your body the raw materials it needs to produce nitric oxide. If you add VasoDrive-AP to that Citrulline, you are simultaneously preventing the breakdown of the enzymes that trigger that NO production, while also stopping the body's natural vasoconstriction mechanisms.
This push-pull synergy is why premium pre-workouts are increasingly combining 6-8 grams of L-Citrulline with 254mg to 508mg of VasoDrive-AP. The Citrulline provides the raw fuel, and the lactotripeptides open the floodgates.
Clinical Dosing and Protocols In clinical settings, studies looking at blood pressure reduction typically use between 3mg and 10mg of the active VPP and IPP peptides. In sports nutrition, the trademarked ingredient VasoDrive-AP is standardized to contain these active peptides.
The industry standard dose for VasoDrive-AP is 254mg per serving, which yields the clinical amount of VPP/IPP. For advanced users or those looking for maximum vasodilation, a dose of 508mg is often used.
Timing: Lactotripeptides should be taken 45 to 60 minutes before exercise. It takes time for the peptides to survive the digestive tract, enter the bloodstream, and inhibit the ACE enzymes.
Loading: While you will absolutely feel an acute pump from a single dose, clinical data suggests that the endothelial benefits of lactotripeptides compound over time. Taking them daily for 1-2 weeks can lead to a more profound baseline level of vasodilation and arterial flexibility.
Real-World Results: What to Expect If you are used to stimulant-heavy pre-workouts, you need to adjust your expectations for lactotripeptides. You will not feel a rush of energy, your heart won't race, and your skin won't tingle.
Instead, the experience is entirely physical and localized to the working muscle. About 15 minutes into your workout, as the blood begins to pool in the muscle, you will notice that the pump feels 'denser' than usual. The muscle bellies will feel harder, and vascularity (veins popping) will be more pronounced, especially in the forearms and biceps.
Furthermore, many users report a significant increase in muscular endurance. Because the blood vessels are wider, your heart doesn't have to work as hard to pump oxygenated blood to the muscles. This improved microcirculation helps flush out lactic acid, allowing you to squeeze out an extra rep or two on your heaviest sets.
Safety, Side Effects, and Dairy Allergies Lactotripeptides are generally recognized as safe (GRAS) and have been consumed safely in fermented milk products for centuries. However, there are two important caveats.
First, because they are derived from casein, individuals with severe milk protein allergies should avoid them. Note that this is an allergy to the protein, not lactose intolerance. VasoDrive-AP is virtually lactose-free, so lactose-intolerant individuals can typically use it without gastrointestinal distress.
Second, because lactotripeptides are effective at lowering blood pressure, individuals who already suffer from clinical hypotension (low blood pressure) or those taking prescription blood pressure medications should consult a doctor before use. Combining a natural ACE inhibitor with a pharmaceutical ACE inhibitor can cause blood pressure to drop to unsafe levels, leading to dizziness or fainting.